Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence

Pharmacogenomics Journal

Volumn 14, Issue 2, 2014, Pages 142-150

  Paez D ^a,b   Gerger, A ^a,c   Zhang, W ^a   Yang, D ^a   Labonte, M J ^a,d   Benhanim, L ^a   Kahn, M ^a   Lenz, F ^a   Lenz, C ^a   Ning, Y ^a   Wakatsuki, T ^a   Loupakis, F ^a   Lenz, H J ^a,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d AZUSA PACIFIC UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Colon cancer; Polymorphisms; WNT

Indexed keywords

APC PROTEIN; BETA CATENIN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GUANINE; IRINOTECAN; NOTCH2 RECEPTOR; OXALIPLATIN; SECRETED FRIZZLED RELATED PROTEIN 4; THYMINE; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR GLI1; WNT PROTEIN; WNT5B PROTEIN; WNT5B PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; APC GENE; ARTICLE; AXIN2 GENE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; COLON CANCER; CXXC4 GENE; DKK2 GENE; DKK3 GENE; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERM LINE; GLI1 GENE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NOTCH2 GENE; PRIORITY JOURNAL; SFRP3 GENE; SFRP4 GENE; TCF7L2 GENE; VALIDATION STUDY; WNT5B GENE; ALLELE; COLONIC NEOPLASMS; ETHNIC GROUP; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR RECURRENCE; VERY ELDERLY; WNT SIGNALING PATHWAY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; COLONIC NEOPLASMS; ETHNIC GROUPS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84897409111     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.20     Document Type: Article

References (42)

1. Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96. 1. J Clin Oncol 2007; 25: 3732-3738.
2. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B et al. Colorectal cancer. Lancet 2010; 375: 1030-1047.
4. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010; 15: 390-404.
5. LaBarge MA. The difficulty of targeting cancer stem cell niches. Clin Cancer Res 2010; 16: 3121-3129.
6. Zeki SS, Graham TA, Wright NA. Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 90-100.
7. Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010; 16: 3130-3140.
8. Saif MW, Chu E. Biology of colorectal cancer. Cancer J 2010; 16: 196-201.
9. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-1487.
10. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002; 296: 1644-1646.
11. Akiyama T. Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 2000; 11: 273-282.
12. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16: 3153-3162.
13. Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res 2007; 5: 165-170.
14. Schneikert J, Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007; 56: 417-425.
15. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res 17: 6934-6943.
16. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 2008; 36 (Database issue): D820-D824.
17. Lee PH, Shatkay H. An integrative scoring system for ranking SNPs by their potential deleterious effects. Bioinformatics 2009; 25: 1048-1055.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006; 100: 229-235.
19. Alonzo TA. Standards for reporting prognostic tumor marker studies. J Clin Oncol 2005; 23: 9053-9054.
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.
21. Conneely KN, Boehnke M. So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet 2007; 81: 1158-1168.
22. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009; 10: 468-477.
23. Hlubek F, Brabletz T, Budczies J, Pfeiffer S, Jung A, Kirchner T. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int J Cancer 2007; 121: 1941-1948.
24. Hughes KR, Sablitzky F, Mahida YR. Expression profiling of Wnt family of genes in normal and inflammatory bowel disease primary human intestinal myofibroblasts and normal human colonic crypt epithelial cells. Inflamm Bowel Dis 2011; 17: 213-220.
25. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850.
26. Planutis K, Planutiene M, Nguyen AV, Moyer MP, Holcombe RF. Invasive colon cancer, but not non-invasive adenomas induce a gradient effect of Wnt pathway receptor frizzled 1 (Fz1) expression in the tumor microenvironment. J Transl Med 2013; 11: 50.
27. Shanmugam KS, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B. The functional genetic variant Arg324Gly of frizzled-related protein is associated with colorectal cancer risk. Carcinogenesis 2007; 28: 1914-1917.
28. Berndt SI, Huang WY, Yeager M, Weissfeld JL, Chanock SJ, Hayes RB. Genetic variants in frizzled-related protein (FRZB) and the risk of colorectal neoplasia. Cancer Causes Control 2009; 20: 487-490.
29. Slattery ML, Folsom AR, Wolff R, Herrick J, Caan BJ, Potter JD. Transcription factor 7-like 2 polymorphism and colon cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 978-982.
30. Fernandez-Rozadilla C, de Castro L, Clofent J, Brea-Fernandez A, Bessa X, Abuli A et al. Single nucleotide polymorphisms in the Wnt and BMP pathways and colorectal cancer risk in a Spanish cohort. PLoS One 2010; 5: e12673.
31. Frank B, Hoffmeister M, Klopp N, Illig T, Chang-Claude J, Brenner H. Single nucleotide polymorphisms in Wnt signaling and cell death pathway genes and susceptibility to colorectal cancer. Carcinogenesis 2010; 31: 1381-1386.
32. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004; 14: 319-327.
33. Byeon JS, Jeong JY, Kim MJ, Lee SM, Nam WH, Myung SJ et al. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer 2010; 127: 2758-2767.
34. Hirata H, Hinoda Y, Nakajima K, Kikuno N, Yamamura S, Kawakami K et al. Wnt antagonist gene polymorphisms and renal cancer. Cancer 2009; 115: 4488-4503.
35. Wang X, Goode EL, Fredericksen ZS, Vierkant RA, Pankratz VS, Liu-Mares W et al. Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 2101-2108.
36. Stewart DJCD, Ye Y, Spitz MR, Lu C, Wu X. Wnt pathway pharmacogenetics in lung cancer patients treated with platinum regimens. American Association for Cancer Research 102nd Annual Meeting, Orlando, Florida, USA, 2011.
37. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 2009; 41: 885-890.
38. Hazra A, Fuchs CS, Chan AT, Giovannucci EL, Hunter DJ. Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk. Cancer Causes Control 2008; 19: 975-980.
39. Fu YP, Edvardsen H, Kaushiva A, Arhancet JP, Howe TM, Kohaar I et al. NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. Mol Cancer 2010; 9: 113.
40. Lees CW, Zacharias WJ, Tremelling M, Noble CL, Nimmo ER, Tenesa A et al. Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways. PLoS Med 2008; 5: e239.
41. Naidu R, Yip CH, Taib NA. Genetic variations in transcription factor 7-like 2 (TCF7L2) gene: association of TCF7L2 rs12255372(G/T) or rs7903146(C/T) with breast cancer risk and clinico-pathological parameters. Med Oncol 2012; 29: 411-417.
42. Salpea KD, Gable DR, Cooper JA, Stephens JW, Hurel SJ, Ireland HA et al. The effect of WNT5B IVS3C4G on the susceptibility to type 2 diabetes in UK Caucasian subjects. Nutr Metab Cardiovasc Dis 2009; 19: 140-145.